FindTrial
Sign In

A prospective, multicenter clinical study of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia in the chronic phase

A prospective, multicenter clinical study of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia in the chronic phase

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067575
Enrollment
Unknown
Registered
2023-01-12
Start date
2023-01-12
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia

Interventions

tyrosine kinase inhibitor discontinuation group:N/A

Sponsors

The First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age =3 years, MR 4.0 or above >=2 years; 4. Agreed to regularly monitor BCR-ABL1 by QRT-PCR in peripheral blood.

Exclusion criteria

Exclusion criteria: 1. Previous TKI resistance; 2. A history of blast crisis or accelerated phase; 3. With severe systemic diseases (such as severe heart, lung, liver, kidney, severe malnutrition and other diseases).

Design outcomes

Primary

MeasureTime frame
rate of molecular relapse ;—

Secondary

MeasureTime frame
growth in height;—

Countries

China

Contacts

Public ContactXiaoli Zhang

The First Affiliated Hospital, Sun Yat-sen University

sealuda@sina.com13642638645

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026